Skip to main content
. 2017 Jan 11;8(2):152–161. doi: 10.7150/jca.16523

Figure 4.

Figure 4

Subgroup analyses. Plots of annual AUROCs of FIB-4 index and APRI for HCC incidence after ETV therapy for patients with LC (n=91) (A) and without LC (n=247) (B). No patient in non-LC developed HCC within 2 years after the start of ETV therapy. Plots of annual AUROCs of FIB-4 index and APRI for HCC incidence after ETV therapy for patients with HBe antigen positivity (n=163) (C) and without HBe antigen positivity (n=175) (D).